Nova Pharma Solutions Bhd (XKLS:03006) EBITDA Margin % : 49.99% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Nova Pharma Solutions Bhd EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Nova Pharma Solutions Bhd's EBITDA for the six months ended in Dec. 2023 was RM2.27 Mil. Nova Pharma Solutions Bhd's Revenue for the six months ended in Dec. 2023 was RM4.55 Mil. Therefore, Nova Pharma Solutions Bhd's EBITDA margin for the quarter that ended in Dec. 2023 was 49.99%.

Nova Pharma Solutions Bhd EBITDA Margin % Historical Data

The historical data trend for Nova Pharma Solutions Bhd's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nova Pharma Solutions Bhd EBITDA Margin % Chart

Nova Pharma Solutions Bhd Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBITDA Margin %

Get a 7-Day Free Trial

20.46

-12.80

11.50

22.69

50.84

Nova Pharma Solutions Bhd Semi-Annual Data
	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBITDA Margin %	Get a 7-Day Free Trial											15.75	33.04	12.06	51.55	49.99

Competitive Comparison of Nova Pharma Solutions Bhd's EBITDA Margin %

For the Engineering & Construction subindustry, Nova Pharma Solutions Bhd's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nova Pharma Solutions Bhd's EBITDA Margin % Distribution in the Construction Industry

For the Construction industry and Industrials sector, Nova Pharma Solutions Bhd's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Nova Pharma Solutions Bhd's EBITDA Margin % falls into.

Nova Pharma Solutions Bhd EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Nova Pharma Solutions Bhd's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	5.048	/	9.93
	=	50.84 %

Nova Pharma Solutions Bhd's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	2.272	/	4.545
	=	49.99 %

Nova Pharma Solutions Bhd (XKLS:03006) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Nova Pharma Solutions Bhd EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Nova Pharma Solutions Bhd's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nova Pharma Solutions Bhd (XKLS:03006) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Industrials » Construction » Nova Pharma Solutions Bhd (XKLS:03006) » Definitions » EBITDA Margin %

Traded in Other Exchanges

N/A

Address

Jalan USJ 25/1, Level 5, Suite C-5-1 & 2, Block C, Sky Park, One City, Subang Jaya, SGR, MYS, 47650

Website

http://www.novapharmasolutions.com

Nova Pharma Solutions Bhd provides engineering solutions to pharma and biotech industries. The company's reportable segments include Design fee, Post Design, & Other support fees. Design fee comprises conceptual designs which include user requirement specification, capacity analysis and process scheduling with detailed costing, list of deliverables, details specification of various equipment and processes. Post design fee comprise tendering and procurement support as well as the construction of a plant, & Other support fees comprise of services to assist a customer in the good manufacturing practice document review & gap analysis and assessment. It generates a majority of its revenue from the Design fee segment. Geographically, the company generates a majority of its revenue from Malaysia.

Nova Pharma Solutions Bhd (XKLS:03006) Headlines

No Headlines